NasdaqCM:APDN

Stock Analysis Report

Executive Summary

Applied DNA Sciences, Inc. develops and markets plat based or other DNA technology solution in the United States, Europe, and Asia.

Rewards

Revenue is forecast to grow 48.54% per year

Earnings have grown 2.9% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year

+ 1 more risk


Snowflake Analysis

Limited growth with weak fundamentals.


Similar Companies

Share Price & News

How has Applied DNA Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: APDN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

APDN

2.5%

US Electronic

0.8%

US Market


1 Year Return

-89.1%

APDN

29.8%

US Electronic

22.0%

US Market

Return vs Industry: APDN underperformed the US Electronic industry which returned 29.8% over the past year.

Return vs Market: APDN underperformed the US Market which returned 22% over the past year.


Shareholder returns

APDNIndustryMarket
7 Day0%2.5%0.8%
30 Day-11.1%2.6%1.7%
90 Day-71.0%8.2%5.2%
1 Year-89.1%-89.1%31.1%29.8%24.7%22.0%
3 Year-95.1%-95.1%48.9%44.8%46.9%37.3%
5 Year-96.4%-96.4%80.7%71.7%65.5%47.3%

Price Volatility Vs. Market

How volatile is Applied DNA Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Applied DNA Sciences undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Applied DNA Sciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Applied DNA Sciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Applied DNA Sciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

24.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: APDN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APDN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APDN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: APDN's revenue (48.5% per year) is forecast to grow faster than the US market (7.4% per year).

High Growth Revenue: APDN's revenue (48.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if APDN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Applied DNA Sciences performed over the past 5 years?

2.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: APDN is currently unprofitable.

Growing Profit Margin: APDN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: APDN is unprofitable, but has reduced losses over the past 5 years at a rate of 2.9% per year.

Accelerating Growth: Unable to compare APDN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APDN is unprofitable, making it difficult to compare its past year earnings growth to the Electronic industry (53.7%).


Return on Equity

High ROE: APDN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Applied DNA Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: APDN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: APDN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: APDN has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: APDN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: APDN has a low level of unsold assets or inventory.

Debt Coverage by Assets: APDN has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APDN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: APDN has less than a year of cash runway if free cash flow continues to grow at historical rates of 15.8% each year.


Next Steps

Dividend

What is Applied DNA Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.5%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate APDN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate APDN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APDN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APDN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APDN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Applied DNA Sciences's salary, the management and board of directors tenure and is there insider trading?

7.7yrs

Average management tenure


CEO

James Hayward (65yo)

13.8yrs

Tenure

US$481,327

Compensation

Dr. James A. Hayward, Ph.D.,Sc.D. has been Chief Executive Officer and Chairman of Applied DNA Sciences Inc. (Formerly Known as Prohealth Medical Tech, Inc) since March 17, 2006 and since June 12, 2007 res ...


CEO Compensation Analysis

Compensation vs Market: James's total compensation ($USD481.33K) is about average for companies of similar size in the US market ($USD528.59K).

Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.


Management Age and Tenure

7.7yrs

Average Tenure

53yo

Average Age

Experienced Management: APDN's management team is seasoned and experienced (7.7 years average tenure).


Board Age and Tenure

4.4yrs

Average Tenure

65yo

Average Age

Experienced Board: APDN's board of directors are considered experienced (4.4 years average tenure).


Insider Trading

Insider Buying: APDN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$393,00013 Nov 19
William Montgomery
EntityIndividual
Shares75,000
Max PriceUS$5.24
BuyUS$2,39016 Sep 19
William Montgomery
EntityIndividual
Shares166.95
Max PriceUS$14.32
BuyUS$108,00026 Aug 19
William Montgomery
EntityIndividual
Shares10,000
Max PriceUS$10.80
BuyUS$65,24424 Jan 19
William Montgomery
EntityIndividual
Shares3,500
Max PriceUS$19.00
BuyUS$71,09022 Jan 19
William Montgomery
EntityIndividual
Shares4,000
Max PriceUS$17.79
BuyUS$178,78208 Jan 19
William Montgomery
EntityIndividual
Shares10,000
Max PriceUS$18.63

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25%.


Management Team

  • James Hayward (65yo)

    President

    • Tenure: 13.8yrs
    • Compensation: US$481.33k
  • Janice Meraglia

    Vice President

    • Tenure: 0yrs
  • Tony Benson

    Managing Director of EMEA

    • Tenure: 8.8yrs
  • Judy Murrah (61yo)

    Chief Information Officer & Secretary

    • Tenure: 6.5yrs
    • Compensation: US$368.00k
  • Beth Jantzen (43yo)

    Chief Financial Officer

    • Tenure: 4.8yrs
    • Compensation: US$306.87k
  • Scott Anchin (45yo)

    Director & Strategic Advisor

    • Tenure: 0.08yrs
  • MeiLin Wan

    Vice President of Textile Sales

    • Tenure: 0yrs
  • Clay Shorrock

    General Counsel

    • Tenure: 0yrs
  • Stephen Hughes

    Director of DNA Programs

    • Tenure: 0yrs
  • John Shearman

    Executive Director of Marketing & Cannabis Business

    • Tenure: 0yrs

Board Members

  • Bob Catell (82yo)

    Chairman of Strategic Advisory Board & Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$87.50k
  • James Hayward (65yo)

    President

    • Tenure: 13.8yrs
    • Compensation: US$481.33k
  • Yacov Shamash (69yo)

    Independent Director

    • Tenure: 13.8yrs
    • Compensation: US$94.70k
  • Ray Kelly (78yo)

    Member of Strategic Advisory Board

    • Tenure: 2.9yrs
  • Joe Ceccoli (57yo)

    Independent Director

    • Tenure: 5yrs
    • Compensation: US$87.50k
  • Sanford Simon (77yo)

    Independent Director

    • Tenure: 13.8yrs
    • Compensation: US$80.40k
  • Mehmood Khan (60yo)

    Member of Strategic Advisory Board

    • Tenure: 3.2yrs
  • John Bitzer (58yo)

    Independent Director

    • Tenure: 8.3yrs
    • Compensation: US$81.30k
  • Gunther Faber

    Member of Strategic Advisory Board

    • Tenure: 3.8yrs
  • Scott Anchin (45yo)

    Director & Strategic Advisor

    • Tenure: 0.08yrs

Company Information

Applied DNA Sciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Applied DNA Sciences, Inc.
  • Ticker: APDN
  • Exchange: NasdaqCM
  • Founded: 1983
  • Industry: Electronic Equipment and Instruments
  • Sector: Tech
  • Market Cap: US$13.732m
  • Shares outstanding: 3.49m
  • Website: https://www.adnas.com

Number of Employees


Location

  • Applied DNA Sciences, Inc.
  • 50 Health Sciences Drive
  • Stony Brook
  • New York
  • 11790
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APDNNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2002
UDJPDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2002
0HGQLSE (London Stock Exchange)YesCommon StockGBUSDNov 2002

Biography

Applied DNA Sciences, Inc. develops and markets plat based or other DNA technology solution in the United States, Europe, and Asia. The company’s supply chain security and product authentication solutions  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/15 23:42
End of Day Share Price2019/12/13 00:00
Earnings2019/09/30
Annual Earnings2019/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.